1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Medical - Devices
Lattice Biologics Ltd.

Lattice Biologics Ltd.

LBLTF
Lattice Biologics Ltd.US flagOther OTC
0.00
USD
- -
- -
16,545.00Market Cap
2007 Y
2008 Y
2009 Y
2010 Y
2011 Y
2012 Y
2013 Y
2014 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
TTM
Revenue per Share
- -
- -
- -
- -
- -
- -
- -
- -
0.08
0.04
0.01
0.02
0.02
0.01
Basic EPS, GAAP
-1.16
-7.63
-0.2
-0.91
-13.7
-0.2
-0.24
-0.26
-0.16
-0.02
-0.01
-0.01
-0.01
-0.01
Free Cash Flow per Basic Share
-13.64
-5.08
-0.97
-0.83
-0.34
-0.07
-0.03
-0.01
-0.05
-0.01
- -
- -
- -
-0.01
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
-6.73
11.81
-13.15
-14.5
-26.54
-27.3
-25.75
-23.87
-0.26
-0.06
-0.06
-0.07
-0.07
- -
Tangible Book Value per Share
26.55
15.01
15.58
15.89
0.13
-0.03
-0.18
-0.24
-0.15
-0.07
-0.07
-0.08
-0.07
- -
Basic Weighted Avg Shares
1
2
2
2
2
2
2
2
48
78
93
93
103
128
Sales/Revenue/Turnover
- -
- -
- -
- -
- -
- -
- -
- -
4
3
1
2
2
2
Operating Margin (%)
- -
- -
- -
- -
- -
- -
- -
- -
-91.32
-102.74
-128.48
-26.75
-10.73
-34.93
Depreciation Expense
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Net Income, GAAP
-2
-12
- -
-2
-28
- -
- -
-1
-8
-2
-1
-1
-1
-1
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
- -
- -
- -
- -
- -
- -
- -
- -
-207.84
-55.66
-106.58
-46.23
-60.16
-59.29
Working Capital
4
2
-2
- -
- -
- -
- -
- -
-5
-4
-5
-7
-7
-1
LT Debt
- -
8
5
- -
- -
- -
- -
- -
1
- -
1
- -
1
- -
Total Equity
39
24
28
29
- -
- -
- -
- -
-6
-4
-5
-6
-6
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -

Capital Structure

FRC

•

in mil. unless spec.
Dec'21
Mar'21
Jun'21
ST Debt
2
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
1
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
128
128
128
Market Capitalization
3
6
3

Working Capital

FRC

•

in mil. unless spec.
Dec'21
Mar'21
Jun'21
Total Current Assets
1
- -
- -
Cash, Cash Equivalents & STI
- -
- -
- -
Accounts Receivable, Net
- -
- -
- -
Inventories
1
- -
- -
Total Current Liabilities
8
2
1
Payables & Accruals
5
2
1
ST Debt
2
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
149.31%
230.67%
1.4%
Free Cash Flow
731.74%
1,515%
-151%
Net Income, GAAP
318.5%
268.92%
46.52%
Sales/Revenue/Turnover
- -
- -
12.6%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2019
- -
1
- -
1
2
2020
1
- -
1
1
2
2021
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2019
- -
- -
- -
- -
-0.01
2020
- -
-0.01
- -
- -
-0.01
2021
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2019
- -
- -
- -
- -
- -
2020
- -
- -
- -
- -
- -
2021
- -
- -
- -
- -
- -

Company Description

APIChat
CEO
Donna Medina
Sector
Healthcare
Industry
Medical - Devices
Address
512 East Madison Avenue Belgrade MT United States of America 59714
IPO Date
Dec 16, 2010
Website
latticebiologics.com
Similar Companies
ProSomnus, Inc. (OSAPQ)
Intuitive Surgical, Inc. (ISRG)
908 Devices Inc. (MASS)
EBR Systems, Inc. (EBRCZ)
Boston Scientific Corporation (0HOY.L)
OK Biotech Co., Ltd. (4155.TW)
Business
Lattice Biologics Ltd. (LBLTF) is a biotechnology company that develops, manufactures, and markets biologic allograft products for cellular therapies and tissue engineering, with a focus on bone, skin, and cartilage regeneration. The company offers acellular demineralized bone scaffolds for orthopedic, neurological, trauma, oral/maxillofacial, and reconstructive procedures; acellular dermal matrices that promote cellular ingrowth, tissue vascularization, and regeneration; amniotic fluid-based products including AmnioBoost and AmnioBlast; soft tissue allografts; dental allografts; membrane and barrier allografts; and demineralized bone matrix allografts, targeting applications such as spinal fusion, dental bone regeneration, sports medicine including ACL repair, breast reconstruction, wound repair, and joint surgeries. Products serve surgeons in dental clinics, orthopedic clinics, ambulatory surgical centers, hospitals, and aesthetic clinics worldwide, with operations centered in the United States and international markets. Founded in 1989 and headquartered in Belgrade, Montana, the company maintains laboratory and manufacturing facilities there, including ISO Class 1000 and ISO Class 100 clean rooms, along with offices in Phoenix, Arizona. In recent years, Lattice Biologics has pursued strategic shifts including a 2021 reorganization to emphasize psychedelics and cannabis markets via a new life sciences subsidiary combining psychedelic products with stem cell regenerative compounds; earlier developments encompassed room-temperature AmnioBoost for dental markets, reformulated DBM putty, DBM fiber plugs, and modified extracellular matrix for stem cell applications with provisional patents; and historical moves such as a reverse merger, debt-to-equity conversions, private placements, and a 2015 acquisition interest by Blackstone Ventures, though no major funding, acquisitions, or partnerships have been publicly reported since 2021.